ArticlePloS one2025
Valorization of various lignocellulosic wastes to Ganoderma lucidum (Curtis) P. Karst (Reishi Mushroom) cultivation and their FT-IR assessments.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biotechnological potential of Ganoderma species in mycoremediation: a bibliometric analysis.Folia microbiologica · 2026Review
- Selected nutritional properties of Ganoderma lucidum and substrate degradation during multi-cycle reuse with hazelnut branch waste.Scientific reports · 2025Article
- Genomic and Transcriptomic Insights into Carbon-Source and Temporal Induction of a Diverse Set of Lignocellulolytic Enzymes inJournal of fungi (Basel, Switzerland) · 2025Article
- Preparation of fungal biocomposite for environment friendly packaging of plant saplings.World journal of microbiology & biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ganoderma lucidum (Curtis) P. Karst (Reishi) has significant pharmacological benefits, and optimizing its cultivation on diverse substrates enhances its commercial viability. This study explored the valorization of various lignocellulosic wastes for cultivating G. lucidum mushrooms, highlighting its potential contributions to sustainable agriculture and waste management. In this research, mushrooms were cultivated using hazelnut branches (HB), hazelnut husk (HH), wheat straw (WS), rhododendron branches (RD), oak wood (OW), beech wood (BW), corn husk (CH), and spent coffee grounds (CG). The biodegradation properties of the mushrooms on the selected substrates were also investigated. HB and RD materials were used for the first time to cultivate and assess the biodegradation properties of G. lucidum. Substrates were prepared for cultivation at varying compositions (91% substrate + 9% wheat bran (WB) and 75% HB + 25% other substrates). The nutritional properties of the mushrooms and substrates, the chemical composition (holocellulose, alpha cellulose, extractives, and ash) of the substrates, and Fourier Transform Infrared Spectroscopy (FT-IR) assessments before and after cultivation were analyzed. Among the substrates, OW 91% + WB 9% yielded the highest mushroom production (46 g/kg), whereas CH (18.3 g/kg) resulted in the lowest yield, with no significant difference compared to WS (18.5 g/kg). Following mushroom cultivation, the holocellulose content and pH values of the substrates decreased proportionally, while alpha-cellulose, extractives, and ash content increased. Chemical analysis revealed an average holocellulose reduction of 13.5% and α-cellulose increase of 32%, alongside substrate-dependent phenolic content variations, with the highest level (3.156 mg GAE/g) observed in beech wood-grown specimens. FT-IR spectra indicated that this method could effectively elucidate the biodegradation properties of G. lucidum on lignocellulosic materials before and after cultivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.